Hybrigenics’ Inecalcitol Shows High Level Of Tolerance
Hybrigenics announces today the commencement results from its Wind up I clinical trial of inecalcitol, a mock analogue of vitamin D under enlargement by Hybrigenics as a potential treatment for prostate cancer.
Inecalcitol was administered orally in a twin-blind randomized boning up against placebo on 36 healthy volunteers up to 80 micrograms. No side effects were observed. In particular, there was neither hypercalcemia, nor rise in calcium levels in the urine, the usual individual dispense-limiting toxicity total standard or synthetic derivatives of vitamin D. Additional higher dose levels of inecalcitol are being prepared conducive to forward testing.
This observation is in line with the demean toxicity of inecalcitol demonstrated in pre-clinical studies as compared to calcitriol, the unpretentiously sprightly metabolite of vitamin D3. Calcitriol is currently in Phase III clinical check for hormone-refractory prostate cancer in combination with Taxotere(R), the first-crease gold standard chemotherapeutic intravenous treatment for this indication. Calcitriol is administered orally in 45 microgram doses aeons ago a week.
“The results of our cardinal Status I trial posture Hybrigenics as a clinical station drug development company,” said Rémi Delansorne, CEO of Hybrigenics, “We expect inecalcitol to be given in higher dosages than calcitriol conducive to more efficacy combined with a better tolerance in the same prostate cancer indication.” Hybrigenics is planning to start the Phase IIa trial to regulate the maximum tolerated dose of inecalcitol in hormone-refractory prostate cancer before the extent of this year.
About Hybrigenics
Hybrigenics is a biopharmaceutical company advancing its R&D programs in oncology, and providing cutting-edge discovery services to identify, validate or curb protein-protein interactions through despite customers from all life sciences.
Hybrigenics is developing inecalcitol, a synthetic vitamin D analogue more potent and less toxic than naturally physical vitamin D compounds. The primary indication of interest for Hybrigenics is prostate cancer by the oral route. Hybrigenics’ research focuses on internally validated Ubiquitin-Specific Proteases (USP) as an true class of oncology targets, and on drug discovery to regard USP inhibitors as novel anti-cancer therapeutics.
Hybrigenics’ services present oneself reliable Yeast Two-Composite screens performed on a robust ISO 9001 certified industrial platform and backed by strong bioinformatics to gather and rank the protein-protein interactions detected. Hybrigenics is also providing study work reinforcement or experimental whip into shape to validate the relevant interactions and to screen for parsimonious molecule inhibitors masterful to into them.
http://www.hybrigenics.com
Gerardo Burney